Home Newsfeeds Atlantic Equities Maintains Neutral on Johnson & Johnson, Raises Price Target to $168

Atlantic Equities Maintains Neutral on Johnson & Johnson, Raises Price Target to $168

Atlantic Equities analyst Steve Chesney maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target from $160 to $168.

byBenzinga Newsdesk

January 25, 2023

1 minute read

Atlantic Equities analyst Steve Chesney maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target from $160 to $168.

Share Sales, Harassment Allegations And Power Play: Turbulence Hits PulteGroup

By AJ Fabino

July 1, 3:20 PM

The tides of change seem to be relentless at Atlanta-based PulteGroup, Inc (NYSE:PHM), one of the largest home…

PHM

Benzinga Bulls And Bears: Tesla, Apple, Microsoft And Man’s 2021 Shiba Inu Stake Now Worth $3.3M If Kept

By Michael Cohen

October 7, 11:00 AM

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

$SHIB

Wall Street’s Most Accurate Analysts Say Hold These 3 Utilities Stocks With Over 5% Dividend Yields

By Avi Kapoor

December 19, 9:16 AM

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

AGR

FDA Says On Dec. 5, Approved Updated Labeling For The Impella RP System, Based On The PAS Results, With An Update To The Indications For Use Statement

By Benzinga Newsdesk

December 5, 10:37 AM

- Reuters

ABMD

Atlantic Equities Maintains Neutral on Johnson & Johnson, Raises Price Target to $168

Related Posts

Share Sales, Harassment Allegations And Power Play: Turbulence Hits PulteGroup

Benzinga Bulls And Bears: Tesla, Apple, Microsoft And Man’s 2021 Shiba Inu Stake Now Worth $3.3M If Kept

Wall Street’s Most Accurate Analysts Say Hold These 3 Utilities Stocks With Over 5% Dividend Yields

FDA Says On Dec. 5, Approved Updated Labeling For The Impella RP System, Based On The PAS Results, With An Update To The Indications For Use Statement